公开(公告)号：US20140308240A1

公开(公告)日：2014-10-16

申请号：US14292940

申请日：2014-06-02

申请人： MASAJI OKADA (27%) ,  YASUSHI TAKAMORI (20%) ,  NATIONAL HOSPITAL ORGANIZATION, KINKI-CHUO CHEST MEDICAL CENTER (27%) ,  AZBIO CORPORATION (26%)

发明人： Masaji Okada ,  Yasushi Takamori ,  Kazuyuki Ogawa ,  Kinya Nagata

IPC分类号： A61K38/20 ,  A61K38/17

CPC分类号： A61K38/20 ,  A61K38/164 ,  A61K38/1709 ,  A61K38/1729 ,  A61K38/204 ,  A61K38/208 ,  A61K39/04 ,  A61K2300/00

摘要： (Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same.(Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

摘要翻译： （问题）为了提供包含颗粒溶素作为活性成分的感染治疗剂，其副作用小，无细胞毒性，细菌几乎不能获得抗性，以及使用该治疗剂的治疗方法。 （解决问题的手段）本发明提供一种感染治疗剂，其包含15K颗粒溶素，15K颗粒溶素和15K颗粒溶素在体内表达载体的组合，15K颗粒溶素与至少一种选自IL- 6，IL-23或IL-27，15K颗粒溶素在体内表达载体和选自IL-6，IL-23或IL-27中的至少一种白介素或15K颗粒溶素的体内表达载体和HSP65DNA的组合的组合 和IL-12DNA体内表达载体，其对细菌的杀伤作用增强，副作用较小，细菌几乎不能获得抗性，以及使用其的处理方法。